Last reviewed · How we verify

NCT03670225

Evaluating Clinical Acceptance of a NPWT Wound Care System

Completed NA Last updated 20 March 2020
What this trial tests

NA trial testing Invia Motion Endure in Diabetic Foot Ulcer in 10 participants. Completed in 30 January 2020.

Timeline
16 October 2018
Primary endpoint
30 January 2020
30 January 2020

Quick facts

Lead sponsorMedela AG
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date16 October 2018
Primary completion30 January 2020
Estimated completion30 January 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medela AG

Who can join

18 and older, any sex, with Diabetic Foot Ulcer or Pressure Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determine if use of the Medela Invia Motion NPWT system supports acceptable progress towards the goal of therapy when treating patients with a variety of wound types during the evaluation period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

Other Medela AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03670225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing